Read more in section
World U.S. seeks release of geologist in China secrets case Yesterday at 10:15
World 20 years after UN pact, many children still suffer Yesterday at 09:03
World U.S. pledges $275 million for tropical forests in 2010 Two days ago at 18:25
World Somali pirates free UAE-owned cargo ship Two days ago at 18:12
World Egypt recalls ambassador in Algeria after soccer loss Two days ago at 17:27
World Big powers ponder how to punish Iran for nukes Two days ago at 16:44
World Computer glitch causes U.S. flight delays Two days ago at 15:39
World Maldives confirms first H1N1 flu death Two days ago at 14:55
World US pastor gets probation in plastic surgery case Two days ago at 14:41
Most popular World
Glaxo Saudi's sole supplier of H1N1 vaccine for now
November 07 at 13:24Saudi Arabia's vaccination campaign was launched on Saturday and will first focus on pilgrims and health workers.
"For the moment, the only vaccine that has been authorised is the GlaxoSmithKline vaccine Pandemrix," health ministry spokesman Khaled Mirghalani told Reuters.
"We will in the future get vaccines from other clients, from other companies, as soon as they get approved by the SFDA (Saudi Food and Drug Authority)," he said.
Around 3 million Muslim pilgrims from more than 160 countries take part in the haj in the holy city of Mecca most years, including up to 2 million who travel from abroad. Haj this year will start in during the last week of November.
Disease experts from the United States and Arab countries, including Saudi Arabia, have said waves of the H1N1 flu virus spread by pilgrims travelling to and from Mecca for haj could put pressure on healthcare systems around the world.
The pilgrimage provides perfect conditions for the spread of the H1N1 flu virus, which is transmitted by sneezing and physical contact.
The country will launch later this month a second inoculation campaign aimed at schools, Health Minister Abdullah bin Abdul-Aziz al-Rabeea said on Saturday.
GlaxoSmithKline and Sanofi-Aventis <SASY.PA> are among some 25 companies producing pandemic vaccine and other drugmakers including Switzerland's Roche Holding <ROG.VX> are making antivirals for use as a frontline H1N1 drug.
According to the World Health Organization's latest death toll, which is thought to underestimate the total spread of the virus, at least 6, 000 people worldwide have died as a result of an H1N1 infection since its discovery earlier this year in Mexico and the United States. (Reporting by Nael Shyoukhi; Writing by Raissa Kasolowsky)